Fermenta Biotech Ltd

- The document does not explicitly mention any current or future plans for fundraising through debt or equity. - The company is focusing on organic and inorganic growth opportunities with added resources post-merger. - There is no direct reference to issuing new shares or taking on additional debt. - Discussions reveal capital expenditure plans primarily for capacity expansion (e.g., multi-synthesis plant in Dahej with a CAPEX of around Rs 30 crores), which is expected to be funded internally. - Monetisation of real estate assets is ongoing, possibly aimed at raising funds, but specific fundraising plans via equity or debt are not indicated. - No mention of a public or private fundraising round in the visible sections of the report.

- Construction of a multi-synthesis plant in Dahej with a total CAPEX of around Rs 30 crores is underway. - No other major CAPEX is expected in the current financial year. - Pharma division capacity is expected to increase by 25% by Q1 FY22 due to the completion of the Rs 30 crore CAPEX. - The Saykha project involves a planned investment of over Rs 200 crores over the next few years, to be done in a phased manner. - Saykha project will focus on manufacturing minerals, chemical multi synthesis capabilities, and valorizing by-products like wool grease and fish oil to cholesterol. - Commercial production at Saykha is expected to start by FY23 after environment clearance and construction. - The company is also undertaking R&D projects, doubling R&D space, and increasing employees to support future growth.

- The company expects a top-line growth at a CAGR of 15% over the next 5 years. - Capacity utilization is currently around 80% and is expected to increase with new expansions. - A multi-synthesis plant under construction will add ~25% capacity by Q1 FY22. - The pharma division expects a 25% capacity increase by Q1 FY22 from ongoing CAPEX of around Rs. 30 crores. - Demand for Vitamin D3 in the human segment is rising, both domestically and in exports; animal feed demand remains subdued due to factors like COVID impact on meat industry. - New product launches including minerals and premix variants of D3 are planned, aligned with government fortification programs targeting edible oil and milk by FY22. - Strategic partnerships and geographic expansions (Europe, USA) are expected to support growth without significant additional CAPEX.

- The company expects top-line growth at a CAGR of 15% over the next 5 years. - Bulk drug division anticipates achieving an average EBITDA margin of around 25% in the long run despite price volatility. - Capacity expansion ongoing: Multi-synthesis plant at Dahej to increase capacity by ~25% by Q1 FY22. - The pharma division is close to full capacity utilization, with expected 25% capacity increase by FY22 due to Rs 30 crore CAPEX. - The company aims to sustain and improve EBITDA margins through backward integration and volume growth despite feed-grade price pressures. - Real estate monetization is planned but delayed due to COVID-19 uncertainties. - The company is diversifying product offerings (e.g., milk and oil fortification) with expected launches by FY22, targeting new markets. - Overall, earnings and profitability are expected to improve gradually, supported by capacity expansions and product diversification.

- The document does not provide explicit details on the current or expected order book or pending orders for the company. - However, it mentions capacity utilization is close to 80% and above, indicating ongoing demand. - The pharma division is near full capacity utilization, with a planned 25% capacity increase by Q1 FY22. - Bulk drug division is dealing with market volatility, making steady-state predictions difficult. - No specific information on pending orders or size of orderbook is stated. - The company acknowledges increased demand for Vitamin D3 on human side but subdued demand on animal feed side due to industry slowdown. - Supply chain improvements and logistic partnerships (e.g., in Germany) are mentioned, likely supporting order fulfillment. - Overall, detailed order book status is not explicitly disclosed in the provided pages.